Unknown

Dataset Information

0

Evolution from Covalent to Self-Assembled PAMAM-Based Dendrimers as Nanovectors for siRNA Delivery in Cancer by Coupled in Silico-Experimental Studies. Part II: Self-Assembled siRNA Nanocarriers.


ABSTRACT: In part I of this review, the authors showed how poly(amidoamine) (PAMAM)-based dendrimers can be considered as promising delivering platforms for siRNA therapeutics. This is by virtue of their precise and unique multivalent molecular architecture, characterized by uniform branching units and a plethora of surface groups amenable to effective siRNA binding and delivery to e.g., cancer cells. However, the successful clinical translation of dendrimer-based nanovectors requires considerable amounts of good manufacturing practice (GMP) compounds in order to conform to the guidelines recommended by the relevant authorizing agencies. Large-scale GMP-standard high-generation dendrimer production is technically very challenging. Therefore, in this second part of the review, the authors present the development of PAMAM-based amphiphilic dendrons, that are able to auto-organize themselves into nanosized micelles which ultimately outperform their covalent dendrimer counterparts in in vitro and in vivo gene silencing.

SUBMITTER: Laurini E 

PROVIDER: S-EPMC6680776 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evolution from Covalent to Self-Assembled PAMAM-Based Dendrimers as Nanovectors for siRNA Delivery in Cancer by Coupled in Silico-Experimental Studies. Part II: Self-Assembled siRNA Nanocarriers.

Laurini Erik E   Marson Domenico D   Aulic Suzana S   Fermeglia Maurizio M   Pricl Sabrina S  

Pharmaceutics 20190710 7


In part I of this review, the authors showed how poly(amidoamine) (PAMAM)-based dendrimers can be considered as promising delivering platforms for siRNA therapeutics. This is by virtue of their precise and unique multivalent molecular architecture, characterized by uniform branching units and a plethora of surface groups amenable to effective siRNA binding and delivery to e.g., cancer cells. However, the successful clinical translation of dendrimer-based nanovectors requires considerable amounts  ...[more]

Similar Datasets

| S-EPMC6680565 | biostudies-literature
| S-EPMC3511617 | biostudies-literature
2013-11-12 | GSE41333 | GEO
| S-EPMC2654094 | biostudies-literature
| S-EPMC3367133 | biostudies-literature
| S-EPMC6415388 | biostudies-literature
| S-EPMC3532938 | biostudies-literature
| S-EPMC4660915 | biostudies-literature
2013-11-12 | E-GEOD-41333 | biostudies-arrayexpress
| S-EPMC2739987 | biostudies-literature